PF-Atlas › Clinical Trials › NCT01685801

Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function

Ivacaftor · Phase 2

Registry ID
NCT01685801
Phase
Phase 2
Status
Completed
Drug / intervention
Ivacaftor
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2012-09

About this trial

Ivacaftor is evaluated in NCT01685801, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Vertex Pharmaceuticals Incorporated. Current status: Completed.

View NCT01685801 on ClinicalTrials.gov →

Explore related

All Ivacaftor trialsAll IPF trials

Related trials

ivacaftor — NCT02445053Ivacaftor — NCT00953706Ivacaftor — NCT01614457Ivacaftor — NCT01705145Ivacaftor — NCT02934698Ivacaftor — NCT03068312
Medical disclaimer. This page summarizes public trial data for NCT01685801 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.